Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + simvastatin
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telmisartan + simvastatin is a fixed-dose combination of two small-molecule drugs: telmisartan, an angiotensin II receptor blocker (ARB) with additional peroxisome proliferator-activated receptor gamma (PPARγ) agonist activity, and simvastatin, a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin). This combination is intended to address both hypertension and hypercholesterolemia, two significant cardiovascular risk factors. Telmisartan works by blocking angiotensin II type 1 (AT1) receptors, thereby lowering blood pressure and exerting vasoprotective effects, while also activating PPARγ, which may confer additional endothelial and metabolic benefits. Simvastatin reduces cholesterol synthesis in the liver by inhibiting HMG-CoA reductase, leading to decreased LDL cholesterol and overall atherogenic risk. Combination therapy with these agents has been shown in preclinical studies to have an additive effect on increasing the number and function of endothelial progenitor cells (EPCs), suggesting synergistic cardiovascular protective mechanisms operating through PPARγ-dependent pathways (for telmisartan) and PI3K/Akt signaling (for simvastatin)[1][3][5].
- Other names
- telmisartan and simvastatin combinationtelmisartan / simvastatin combination
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)PPARG (Peroxisome proliferator-activated receptor gamma)LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on telmisartan + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + simvastatin.